Cardiovascular

Increasing use of SGLT-2 inhibitors among patients with heart failure.

TL;DR

A multimodal quality improvement intervention involving pharmacy and primary care effectively increased SGLT-2 inhibitor prescribing in eligible patients with heart failure, from 7.1% to 9.0%.

Key Findings

SGLT-2 inhibitor prescribing among eligible heart failure patients increased after the intervention, from 7.1% to 9.0%.

  • Pre-intervention prescribing was 7.1% (n = 630); post-intervention prescribing was 9.0% (n = 814).
  • This represents a relative increase of 26.8% from baseline.
  • Prescription percentages were identified using the health system's heart failure registry.

The project identified underutilization of SGLT-2 inhibitors in eligible patients with heart failure across the health system and targeted barriers contributing to it.

  • The stated objective was to identify and address barriers contributing to underutilization of SGLT-2 inhibitors.
  • Baseline prescribing in eligible patients was low (7.1%).

The intervention combined pharmacist education to primary care providers with a cost information handout.

  • The multimodal approach involved both pharmacy and primary care.
  • The interventions were designed to increase prescribing among primary care providers.

The authors concluded that physician associates, as a key part of the primary care workforce, play an important role in initiating guideline-directed medical therapy.

  • Physician associates are described as a key part of the primary care workforce.
  • The conclusion relates to initiation of guideline-directed medical therapy for heart failure.

What This Means

This quality improvement project looked at why a type of medication called SGLT-2 inhibitors was rarely prescribed to people with heart failure who could benefit from it across one health system. The team used a heart failure registry to track how often eligible patients were prescribed these drugs before and after the intervention. The interventions were pharmacist education for primary care providers and a handout with cost information. After these steps, prescribing in eligible patients rose from 7.1% to 9.0%, a relative increase of about 27%. Although prescribing remained low in absolute terms, the change suggests that combining pharmacy and primary care efforts can help move these guideline-recommended medications into use. The authors point to physician associates and other primary care clinicians as important players in starting guideline-directed heart failure therapy. This was a quality improvement project rather than a controlled trial, so this research suggests the approach is promising but does not prove it was the sole cause of the change.

Have a question about this study?

Citation

Hoppe N, Haugh S, Umbreit A, Morlock M, Sathre J, Johnson J, et al.. (2026). Increasing use of SGLT-2 inhibitors among patients with heart failure.. JAAPA : official journal of the American Academy of Physician Assistants. https://doi.org/10.1097/01.JAA.0000000000000396